AN ACT to amend Tennessee Code Annotated, Title 33; Title 38; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to buprenorphine.
Impact
If enacted, SB2292 will potentially impact the administrative processes surrounding buprenorphine treatment by requiring more frequent reporting. This could enhance the state's ability to track the effectiveness of opioid addiction treatments and ensure compliance with standards. By mandating an earlier reporting date, the bill could facilitate quicker responses to any issues arising within the prescription and distribution of buprenorphine, thereby improving treatment oversight.
Summary
Senate Bill 2292 aims to amend various sections of the Tennessee Code Annotated related to the regulation and handling of buprenorphine, a medication used in the treatment of opioid addiction. The primary focus of the bill is to adjust the reporting requirements for buprenorphine administration, specifying that reports should be submitted by February 1 of each year. This change is seen as a step towards streamlining monitoring processes related to the distribution and usage of buprenorphine, which is vital in combating the opioid crisis affecting many communities in Tennessee.
Sentiment
The sentiment surrounding SB2292 is generally positive among healthcare advocates who see it as a necessary improvement to the current regulations governing substance use treatment. Supporters argue that improved tracking and monitoring can lead to better outcomes for individuals seeking help for opioid addiction. However, some concerns remain regarding the administrative burden on healthcare providers and whether the changes will lead to substantial improvements in treatment accessibility and quality.
Contention
Notable points of contention among stakeholders include the balance between regulatory oversight and the operational realities faced by treatment providers. Some argue that the new reporting requirement might overwhelm already strained resources within healthcare settings. Others worry that while the intention is to improve treatment efficacy and monitoring, the implementation may not adequately consider the complexities involved in patient care and treatment variability across different regions.
Crossfiled
AN ACT to amend Tennessee Code Annotated, Title 33; Title 38; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to buprenorphine.
AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.
AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.
AN ACT to amend Tennessee Code Annotated, Title 4; Title 9; Title 29; Title 33; Title 37; Title 38; Title 39; Title 40; Title 53; Title 56; Title 62; Title 63; Title 68 and Title 71, relative to abortion.
AN ACT to amend Tennessee Code Annotated, Title 4; Title 9; Title 29; Title 33; Title 37; Title 38; Title 39; Title 40; Title 53; Title 56; Title 62; Title 63; Title 68 and Title 71, relative to abortion.
AN ACT to amend Tennessee Code Annotated, Title 28; Title 29; Title 33; Title 38; Title 39; Title 53; Title 63; Title 68 and Title 71, relative to drug overdoses.
AN ACT to amend Tennessee Code Annotated, Title 4; Title 29; Title 33; Title 37; Title 39; Title 40; Title 53; Title 56; Title 62; Title 63; Title 68 and Title 71, relative to women's health.
AN ACT to amend Tennessee Code Annotated, Title 4; Title 29; Title 33; Title 37; Title 39; Title 40; Title 53; Title 56; Title 62; Title 63; Title 68 and Title 71, relative to women's health.
AN ACT to amend Tennessee Code Annotated, Title 4; Title 29; Title 33; Title 38; Title 39; Title 40; Title 41; Title 43; Title 45; Title 50; Title 53; Title 63; Title 67; Title 68 and Title 71, relative to cannabis.